The first study included COVID-19 patients with CRP > 60 mg/L, and the authors observed decreased CRP, fibrinogen, creatinine, and body temperature, and increased lymphocyte and platelet counts and alanine-transferase activity in all groups of patients 7–10 days after the start of therapy. Here, CRP is linked to COVID-19.